glp-1 dementia study Penn Holderness, a family influencer, has the highest genetic risk for Alzheimer's. He started taking a solely to prevent it, but experts say the research is still emerging. See link below GLP-1 Dementia, Alzheimer's Disease Risks

GLP 1 receptor agonists and dual incretin therapies are delivering measurable, outcome driven results: 12% to 27% relative risk reduction in major adverse cardiovascular events across CVOTs 13% to 14% reduction in cardiovascular death in meta analyses 11% to 14% reduction in hospitalization for heart failure 24% relative risk reduction in kidney outcomes in the dedicated FLOW trial with semaglutide Up to 15.8% weight loss with semaglutide 2.4 mg 20.2% weight loss with tirzepatide 15 mg in head to head obesity trials 66% to 93% reduction in progression from prediabetes to type 2 diabetes This is no longer about glucose (or weight loss) alone

Combining appetite suppressants that work through different mechanisms could theoretically enhance weight loss, but it could also increase the risk and severity of side effects from both medications simultaneously

GLP1 receptor agonists (GLP-1s) are prescription drugs widely used to manage type 2 diabetes, obesity and related chronic conditions such as cardiovascular disease and fatty liver disease

The "52-week window" refers to the timeframe of the Hansen et al